Search
Elevated egg-specific Th2 cytokine responses were established prior to egg ingestion at 4months and were not significantly altered by introduction of egg
The purpose of this article is to highlight emerging evidence for existing allergy prevention guidelines regarding potential benefits of supporting early...
Treatments for food allergy are still lacking, yet progress is being made, and immunotherapy appears more effective than dietary avoidance.
Food allergy (FA) affects 2%-10% of US children and is a growing clinical and public health problem.
The pathogenesis of asthma continues to be a major topic of interest to our authors with reviews and original papers on the role of viruses, mechanisms of...
Food allergy can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments.
Food allergy is mediated by a combination of genetic and environmental risk factors, potentially mediated by epigenetic mechanisms.
The prevalence of allergic diseases across the Australian population, in all regions and age groups, is not well documented. This study aimed to describe the prevalence and distribution of five allergic diseases (allergic rhinitis, asthma, drug allergy, eczema, and food allergy) and examine differences by sociodemographic factors.
The first peanut oral immunotherapy (OIT) for children was approved by the US Food and Drug Administration (FDA) in 2020. While clinical efficacy is established, evidence on cost-effectiveness-whether the benefits outweigh the costs and adverse effects-remains limited. A variant of OIT, known as probiotic and peanut OIT (PPOIT), has shown similar efficacy in trials.
The high burden of peanut allergy underscores the need for treatment options that improve patient health-related quality of life (HRQL). However, the modifying effect of sex assigned at birth on treatment-related outcomes remains poorly understood. We sought to investigate whether sex modifies treatment effect on the change in overall and subdomain HRQL during the PPOIT-003 trial.